Experimental drug aims to reverse liver damage in rare triple condition
NCT ID NCT07681089
First seen Jul 02, 2026 · Last updated Jul 02, 2026
Summary
This study tests a drug called foscenvivint in people with liver cirrhosis caused by HIV and hepatitis C co-infection who also have hemophilia. Participants receive the drug once a week for 24 weeks. Researchers will check if the drug improves liver function and is safe to use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
foscenvivint
What this could lead to
If successful, this could point toward a new treatment option for liver cirrhosis in people with HIV/HCV co-infection and hemophilia.
What could go wrong
This is a very small early-phase trial with only 4 participants, so results may not apply broadly. The drug may not improve liver function or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- RSV Vaccine Trial for Pregnant Women with HIV (NCT06325657)
- Smoking Cessation App for Black Smokers with HIV NCT05709002
- #TranscendentHealth: Text program for trans yout NCT07681908
- HIV and Cerebral Small Vessel Disease Study NCT02210130
- Urine HPV Test for Cervical Cancer Screening (NCT05413798)
- HOPE Study: Hepatitis B & C Long-Term Observatio NCT02995252
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hokkaido University Hospital
Sapporo, Hokkaido, 060-8648, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
National Hospital Organization Osaka National Hospital
Osaka, Osaka, 540-0006, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tokyo Metropolitan Komagome Hospital
Bunkyo-Ku, Tokyo, 113-8677, Japan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact